In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Merck & Company (MRK – Research Report), with a ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck paused ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 years, after the drug company's softer-than-expected guidance amid struggles for its HPV vaccine ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted profits topping expectations.

Merck would take control of Moderna's cancer vaccine franchise, directing and scaling research efforts to maximize the long-term value of KEYTRUDA. Analyst’s Disclosure: I/we have no stock ...

Merck MRK stock has declined 8.8% in the past three months. Merck faces its share of headwinds like declining sales of the human papillomavirus (HPV) vaccine, Gardasil, and diabetes drug ...